Which has preferable valuation and earnings, OLMA or RNA?

Avidity Biosciences is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Olema Pharmaceuticals N/A N/A -$162.45M -$2.12 N/A Avidity Biosciences N/A N/A N/A -$2.15 N/A

Is OLMA or RNA more profitable?

Avidity Biosciences' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -48.26% -43.04% Avidity Biosciences N/A N/A N/A

Does the media refer more to OLMA or RNA?

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Avidity Biosciences. MarketBeat recorded 5 mentions for Olema Pharmaceuticals and 3 mentions for Avidity Biosciences. Olema Pharmaceuticals' average media sentiment score of 0.73 beat Avidity Biosciences' score of 0.28 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, ANL or RNA?

Avidity Biosciences has lower revenue, but higher earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 193.33 -$35.53M N/A N/A Avidity Biosciences N/A N/A N/A -$2.15 N/A

Is ANL or RNA more profitable?

Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Avidity Biosciences N/A N/A N/A

Does the media favor ANL or RNA?

In the previous week, Adlai Nortye and Adlai Nortye both had 3 articles in the media. Adlai Nortye's average media sentiment score of 1.02 beat Avidity Biosciences' score of 0.28 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, RNA or FTH?

Avidity Biosciences is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avidity Biosciences N/A N/A N/A -$2.15 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$141.65 N/A

Is RNA or FTH more profitable?

Avidity Biosciences' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avidity Biosciences N/A N/A N/A Sensei Biotherapeutics N/A -1,012.17% -175.69%

Does the media prefer RNA or FTH?

In the previous week, Sensei Biotherapeutics had 3 more articles in the media than Avidity Biosciences. MarketBeat recorded 6 mentions for Sensei Biotherapeutics and 3 mentions for Avidity Biosciences. Sensei Biotherapeutics' average media sentiment score of 0.63 beat Avidity Biosciences' score of 0.28 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer RIGL or RNA?

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Avidity Biosciences. MarketBeat recorded 5 mentions for Rigel Pharmaceuticals and 3 mentions for Avidity Biosciences. Rigel Pharmaceuticals' average media sentiment score of 1.44 beat Avidity Biosciences' score of 0.28 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DBVT or RNA?

In the previous week, DBV Technologies and DBV Technologies both had 3 articles in the media. Avidity Biosciences' average media sentiment score of 0.28 beat DBV Technologies' score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Avidity Biosciences (RNA) Competitors

$14.19 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

RNA vs. OLMA, ANL, FTH, RIGL, and DBVT

Should you buy Avidity Biosciences stock or one of its competitors? Avidity Biosciences's main competitors and comparable companies include Olema Pharmaceuticals (OLMA), Adlai Nortye (ANL), Sensei Biotherapeutics (FTH), Rigel Pharmaceuticals (RIGL), and DBV Technologies (DBVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Avidity Biosciences compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Olema Pharmaceuticals presently has a consensus target price of $42.40, indicating a potential upside of 294.42%. Avidity Biosciences has a consensus target price of $63.85, indicating a potential upside of 349.94%. Given Avidity Biosciences' higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29

Avidity Biosciences' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-48.26%	-43.04%
Avidity Biosciences	N/A	N/A	N/A

91.8% of Olema Pharmaceuticals shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Avidity Biosciences is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Avidity Biosciences. MarketBeat recorded 5 mentions for Olema Pharmaceuticals and 3 mentions for Avidity Biosciences. Olema Pharmaceuticals' average media sentiment score of 0.73 beat Avidity Biosciences' score of 0.28 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Olema Pharmaceuticals beats Avidity Biosciences on 8 of the 12 factors compared between the two stocks.

How does Avidity Biosciences compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

Adlai Nortye presently has a consensus target price of $24.25, indicating a potential upside of 61.56%. Avidity Biosciences has a consensus target price of $63.85, indicating a potential upside of 349.94%. Given Avidity Biosciences' higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Avidity Biosciences	N/A	N/A	N/A

35.2% of Adlai Nortye shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Adlai Nortye and Adlai Nortye both had 3 articles in the media. Adlai Nortye's average media sentiment score of 1.02 beat Avidity Biosciences' score of 0.28 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avidity Biosciences has lower revenue, but higher earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	193.33	-$35.53M	N/A	N/A
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A

Summary

Adlai Nortye beats Avidity Biosciences on 5 of the 7 factors compared between the two stocks.

How does Avidity Biosciences compare to Sensei Biotherapeutics?

Avidity Biosciences (NASDAQ:RNA) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Avidity Biosciences is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Avidity Biosciences presently has a consensus price target of $63.85, suggesting a potential upside of 349.94%. Sensei Biotherapeutics has a consensus price target of $55.00, suggesting a potential upside of 37.33%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Avidity Biosciences' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	N/A	N/A	N/A
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

In the previous week, Sensei Biotherapeutics had 3 more articles in the media than Avidity Biosciences. MarketBeat recorded 6 mentions for Sensei Biotherapeutics and 3 mentions for Avidity Biosciences. Sensei Biotherapeutics' average media sentiment score of 0.63 beat Avidity Biosciences' score of 0.28 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Sensei Biotherapeutics beats Avidity Biosciences on 7 of the 11 factors compared between the two stocks.

How does Avidity Biosciences compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Avidity Biosciences' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	116.30%	22.95%	17.19%
Avidity Biosciences	N/A	N/A	N/A

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Avidity Biosciences. MarketBeat recorded 5 mentions for Rigel Pharmaceuticals and 3 mentions for Avidity Biosciences. Rigel Pharmaceuticals' average media sentiment score of 1.44 beat Avidity Biosciences' score of 0.28 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Rigel Pharmaceuticals has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	3.06	$367.02M	$16.32	2.98
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A

Rigel Pharmaceuticals presently has a consensus target price of $59.00, suggesting a potential upside of 21.22%. Avidity Biosciences has a consensus target price of $63.85, suggesting a potential upside of 349.94%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29

Summary

Rigel Pharmaceuticals beats Avidity Biosciences on 11 of the 14 factors compared between the two stocks.

How does Avidity Biosciences compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, DBV Technologies and DBV Technologies both had 3 articles in the media. Avidity Biosciences' average media sentiment score of 0.28 beat DBV Technologies' score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avidity Biosciences has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Avidity Biosciences' return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Avidity Biosciences	N/A	N/A	N/A

Avidity Biosciences has lower revenue, but higher earnings than DBV Technologies. Avidity Biosciences is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	150.18	-$146.95M	-$3.51	N/A
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A

DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 260.06%. Avidity Biosciences has a consensus target price of $63.85, suggesting a potential upside of 349.94%. Given Avidity Biosciences' higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29

71.7% of DBV Technologies shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Avidity Biosciences beats DBV Technologies on 6 of the 11 factors compared between the two stocks.

Get Avidity Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNA vs. The Competition

Export

Metric	Avidity Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$242.79M	$4.00B	$7.21B	$12.89B
Dividend Yield	N/A	3.60%	2.54%	9.13%
P/E Ratio	-6.60	12.71	273.82	25.45
Price / Sales	N/A	1,332.35	621.89	100.89
Price / Cash	N/A	45.00	28.92	35.62
Price / Book	N/A	16.39	11.00	6.39
Net Income	N/A	-$22.85M	$3.49B	$358.69M
7 Day Performance	6.53%	1.41%	1.65%	0.22%
1 Month Performance	14.99%	5.98%	4.44%	-0.10%
1 Year Performance	-71.82%	49.29%	24.20%	14.04%

Avidity Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNA Avidity Biosciences	2.0692 of 5 stars	$14.19 flat	$63.85 +349.9%	-71.8%	$242.79M	N/A	N/A	190	Gap Up
OLMA Olema Pharmaceuticals	2.2274 of 5 stars	$10.43 +1.6%	$42.40 +306.5%	+29.4%	$898.60M	N/A	N/A	70	Positive News
ANL Adlai Nortye	1.8111 of 5 stars	$14.19 +2.7%	$24.25 +70.9%	+757.7%	$889.98M	$5M	N/A	127	Positive News Gap Down
FTH Sensei Biotherapeutics	4.0909 of 5 stars	$32.77 -3.2%	$55.00 +67.8%	N/A	$874.44M	N/A	N/A	40	Gap Down
RIGL Rigel Pharmaceuticals	4.3027 of 5 stars	$46.18 -0.6%	$59.00 +27.8%	+17.7%	$859.98M	$294.28M	2.83	160	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNA) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avidity Biosciences (RNA) Competitors

RNA vs. OLMA, ANL, FTH, RIGL, and DBVT

How does Avidity Biosciences compare to Olema Pharmaceuticals?

Summary

How does Avidity Biosciences compare to Adlai Nortye?

Summary

How does Avidity Biosciences compare to Sensei Biotherapeutics?

Summary

How does Avidity Biosciences compare to Rigel Pharmaceuticals?

Summary

How does Avidity Biosciences compare to DBV Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNA vs. The Competition

Avidity Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avidity Biosciences (RNA) Competitors

RNA vs. OLMA, ANL, FTH, RIGL, and DBVT

How does Avidity Biosciences compare to Olema Pharmaceuticals?

Do analysts rate OLMA or RNA?

Is OLMA or RNA more profitable?

Do insiders & institutionals believe in OLMA or RNA?

Which has preferable valuation and earnings, OLMA or RNA?

Does the media refer more to OLMA or RNA?

Summary

How does Avidity Biosciences compare to Adlai Nortye?

Do analysts rate ANL or RNA?

Is ANL or RNA more profitable?

Do institutionals & insiders believe in ANL or RNA?

Does the media favor ANL or RNA?

Which has better valuation & earnings, ANL or RNA?

Summary

How does Avidity Biosciences compare to Sensei Biotherapeutics?

Which has higher earnings & valuation, RNA or FTH?

Do analysts recommend RNA or FTH?

Is RNA or FTH more profitable?

Does the media prefer RNA or FTH?

Do insiders and institutionals hold more shares of RNA or FTH?

Summary

How does Avidity Biosciences compare to Rigel Pharmaceuticals?

Is RIGL or RNA more profitable?

Does the media prefer RIGL or RNA?

Do institutionals & insiders have more ownership in RIGL or RNA?

Which has preferable valuation & earnings, RIGL or RNA?

Do analysts rate RIGL or RNA?

Summary

How does Avidity Biosciences compare to DBV Technologies?

Does the media favor DBVT or RNA?

Is DBVT or RNA more profitable?

Which has stronger valuation and earnings, DBVT or RNA?

Do analysts rate DBVT or RNA?

Do insiders and institutionals hold more shares of DBVT or RNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNA vs. The Competition

Avidity Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools